drugset / Trial / NCT06750432
PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)
RandomizedSequentialDouble-blindTreatment
Summary
This Phase 1b study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of multiple IV infusions of PMN310 in patients with early Alzheimer's disease.
Timeline
- Start
- 2024-12-13
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PMN310 | Monoclonal antibody | 350 mg | Intravenous |
| Subject | PMN310 | Monoclonal antibody | 700 mg | Intravenous |
| Subject | PMN310 | Monoclonal antibody | 1400 mg | Intravenous |